Natural health advocates have long understood that the pharmaceutical lobby is the biggest block to nutritional and Cellular Medicine therapies becoming mainstream. Through directing funding to politicians, health organizations, and the mainstream media, drug companies seek to maintain a vice-like grip over the practice of medicine. However, a new study published by researchers from the German Cancer Research Center – a European citadel for orthodox cancer approaches – suggests we may be on the verge of a new era. Analyzing data from 14 randomized, placebo-controlled trials, it confirms that daily doses of vitamin D3 reduce mortality from cancer. With vitamin D deficiency known to be a worldwide problem, the study represents a significant challenge to the interests of the multibillion-dollar cancer drug business.
Published in the Ageing Research Reviews journal, the study takes the form of a systematic review and meta-analysis of randomized, placebo-controlled trials and individual patient data. Examining a total of 104,727 participants, the analysis reveals that in the 10 trials utilizing a daily dosing regimen there was a 12 percent lower cancer mortality in the vitamin D3 group compared to the placebo group. Significantly, however, no mortality reduction was seen in the other 4 trials which, instead of daily doses, gave higher doses of the vitamin at longer intervals.
The researchers also found that the mortality reduction effect was most noticeable when vitamin D3 supplementation was started prior to a cancer diagnosis, as opposed to after one. Nevertheless, the reduction in cancer mortality following administration of the vitamin was observed in study participants both with and without vitamin D deficiency.
The significance of the new study should not be underestimated. The German Cancer Research Center that carried out the analysis has close links to the pharmaceutical industry. Its corporate partners include Bayer, with whom it works on drug discovery and development, and the Boehringer Ingelheim Foundation, which provides additional project funding. If translated into government health policy and clinical practice, the finding that daily doses of vitamin D3 reduce mortality from cancer would undoubtedly represent a significant economic threat to these interests.
This threat is further magnified by the increasing recognition that vitamin D deficiency is a worldwide problem. In the United States and Canada, deficiency is well known to be widespread. In Europe blood levels of vitamin D have been shown to be low in 50 to 70 percent of the population, with India also now home to a growing epidemic of the problem. Even in Australia, a country where people typically enjoy an outdoor lifestyle with plentiful sunshine, deficiency is said to have reached crisis levels. High rates of vitamin D deficiency are also commonplace in Africa.
With daily doses of vitamin D clearly able to reduce mortality from cancer and deficiency proven to be widespread, pressure will inevitably now build on the medical orthodoxy to act on this knowledge and switch its main focus to prevention. As we shall examine next, the widespread use of vitamin D and other natural approaches has the potential to save millions of lives.
The vitamin D study adds to a growing body of evidence over the past two decades showing that science-based natural health approaches are effective in the prevention and control of cancer. The event that triggered this rise in interest came in early 2002 when, in findings presented at the 19th Annual Miami Breast Cancer Conference in Florida, Dr. Rath and his research team announced a revolutionary breakthrough in the natural control of cancer. Proving that a micronutrient combination consisting of vitamin C, lysine, proline, and specific extracts from green tea can inhibit the spread of cancer cells, their work provided the impetus for numerous other researchers worldwide, including those working in government institutions, to begin studying the use of micronutrients for fighting the disease.
Subsequently, a key step towards ‘official’ recognition of the use of vitamin C against cancer came in a study published in the prestigious Proceedings of the National Academy of Sciences of the United States of America in September 2005. Authored by scientists at the U.S. government’s National Institutes of Health (NIH), the world’s largest research institute, the study confirmed that vitamin C selectively kills cancer cells. This is in contrast to chemotherapy drugs which, through intoxicating the entire body, kill cancer cells and billions of healthy cells alike. The NIH researchers wrote that their findings give plausibility to the use of intravenous vitamin C in the treatment of cancer.
The ongoing work conducted at the Dr. Rath Research Institute has since proved that a synergistic group of micronutrients including vitamin C can inhibit the invasion of more than 40 different types of human cancer. When used in combination these micronutrients are able to inhibit cancer cell invasion and metastasis, inhibit cancer cell multiplication and tumor growth, inhibit the formation of new blood vessels that feed tumors (angiogenesis), and induce the natural death of cancer cells (apoptosis). Significantly, there is no drug anywhere in the world that can effectively and safely achieve all of these things. As Dr. Rath and Dr. Niedzwiecki observed in their 2011 book, ‘Victory Over Cancer’, effectively blocking even one of these mechanisms can be sufficient to control cancer.
With the United States Patent Office recently awarding the Dr. Rath Research Institute a game-changing patent on a specific combination of micronutrients for protecting healthy cell growth, the threat to the drug-based cancer establishment is clear. As such, with a revolution in the control of cancer now possible, patients, their families, and physicians have a right to be told the facts.